Immuron FY23 Sales increase 136% on FY22 Sales
2023年7月5日 - 7:00PM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company is pleased to
announce FY23 sales (unaudited net sales) results of its
over-the-counter gastrointestinal and digestive health immune
supplement Travelan® and Protectyn®.
Sales of Travelan® and Protectyn® increased by
136% in FY23 to AUD $1.80 M, compared to AUD $765 k in
FY22.
In Australia, Travelan® and Protectyn® sales for
FY23 were AUD $1.16 M, a 478% increase on FY22 sales (AUD $201 k).
Travelan® sales increase as overseas travel rebounds. Australian
resident short term departures in April 2023 were 82% of those in
April 2019 (Australian Bureau of Statistics).
Immuron previously reported that strong sales of
Travelan® may result in short term stock outages in some
wholesalers and pharmacies in the June 2023 quarter. This did
occur. While Immuron does have inventory of Travelan® Australia
ready to release, it is unable to do so until it has received GMP
Clearance from the Therapeutic Goods Administration (TGA). Even
though Immuron has transferred and validated the transfer of
packaging to another supplier which has a valid/current GMP
certificate from the TGA, the TGA is unable to give Immuron a
timeline for GMP Clearance. The TGA advises that it is experiencing
extremely high volumes of GMP Clearance extension applications
which is resulting in delays to processing timeframes.1 Immuron
shall continue to press for an early resolution of this issue with
the TGA.
USA Travelan® FY23 sales were AUD $643 k, a 28%
increase on FY22 sales (AUD $501 k). This growth was attributable
to increasing sales in both Passport Health Travel Clinics and
distributor sales. FY23 sales were impacted by supply constraints.
These have been resolved. Immuron has inventory of Travelan® USA on
hand, sufficient to meet the needs of its current customers and to
expand into new market segments. Immuron has shipped inventory to
Amazon with launch anticipated in the next couple of weeks.
Immuron is focused on growing sales of its
commercial products, expanding its portfolio of products and has a
strong existing pipeline.
- Australian Government Department of Health and Aged
Care Therapeutic Goods Administration
This release has been authorised by the directors of Immuron
Limited.
COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 5 2024 まで 6 2024
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 6 2023 まで 6 2024